Antiplatelet and anticoagulant therapies in acute coronary syndromes

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is the cornerstone treatment for acute coronary syndromes (ACS).
• Significant controversies persist regarding optimal aspirin and clopidogrel dosing, initiation timing, and treatment duration in ACS management.
• The concept of clopidogrel resistance presents potential clinical challenges.

Purpose of the Study:

• To review current controversies and emerging concepts in antiplatelet and anticoagulant therapy for acute coronary syndromes.
• To evaluate the evolving role of glycoprotein IIb/IIIa inhibitors and newer anticoagulants in ACS.

Main Methods:

• Literature review of current evidence and clinical guidelines on antiplatelet and anticoagulant therapies in ACS.
• Analysis of emerging concepts such as clopidogrel resistance and the comparative effectiveness of newer agents.

Main Results:

• Dosing, initiation, and duration of aspirin and clopidogrel therapy in ACS remain subjects of ongoing debate.
• Clopidogrel resistance is a recognized phenomenon with potential clinical significance.
• Newer anticoagulants like bivalirudin and fondaparinux demonstrate improved outcomes in specific ACS management strategies compared to heparin.
• Glycoprotein IIb/IIIa inhibitors have a reduced but still defined role in high-risk ACS populations.

Conclusions:

• The standard of care for ACS involves combining multiple antiplatelet agents with an anticoagulant.
• Further research is needed to clarify optimal antiplatelet strategies and address clopidogrel resistance.
• Individualized treatment approaches considering patient risk and specific agent profiles are crucial for managing ACS.